Literature DB >> 15283875

Virus subversion of protective immunity.

Eric W Hewitt1, Gillian E Dugan.   

Abstract

The major histocompatibility (MHC) class I antigen presentation pathway plays a pivotal role in immunity to viruses. MHC class I molecules are expressed on the cell surface of all nucleated cells and present peptides derived from intracellular proteins to cytotoxic T lymphocytes (CTLs), which then eliminate virally infected cells. However, many viruses have evolved proteins to inhibit the MHC class I pathway, thus enabling virally infected cells to escape CTL lysis. In this review, we summarize recent findings about viral inhibition of the MHC class I pathway.

Mesh:

Year:  2004        PMID: 15283875     DOI: 10.1007/s11882-004-0085-2

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  47 in total

1.  Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins.

Authors:  S Ishido; C Wang; B S Lee; G B Cohen; J U Jung
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 2.  Structure--function relationships in HIV-1 Nef.

Authors:  M Geyer; O T Fackler; B M Peterlin
Journal:  EMBO Rep       Date:  2001-07       Impact factor: 8.807

3.  Optimization of the MHC class I peptide cargo is dependent on tapasin.

Authors:  Anthony P Williams; Chen Au Peh; Anthony W Purcell; James McCluskey; Tim Elliott
Journal:  Immunity       Date:  2002-04       Impact factor: 31.745

4.  HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway.

Authors:  Anastassia D Blagoveshchenskaya; Laurel Thomas; Sylvain F Feliciangeli; Chien Hui Hung; Gary Thomas
Journal:  Cell       Date:  2002-12-13       Impact factor: 41.582

5.  HIV Nef-mediated major histocompatibility complex class I down-modulation is independent of Arf6 activity.

Authors:  Jakob E Larsen; Ramiro H Massol; Thomas J F Nieland; Tomas Kirchhausen
Journal:  Mol Biol Cell       Date:  2003-11-14       Impact factor: 4.138

6.  Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.

Authors:  J Levitskaya; A Sharipo; A Leonchiks; A Ciechanover; M G Masucci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

7.  The SH3 domain-binding surface and an acidic motif in HIV-1 Nef regulate trafficking of class I MHC complexes.

Authors:  M E Greenberg; A J Iafrate; J Skowronski
Journal:  EMBO J       Date:  1998-05-15       Impact factor: 11.598

8.  A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter.

Authors:  H Hengel; J O Koopmann; T Flohr; W Muranyi; E Goulmy; G J Hämmerling; U H Koszinowski; F Momburg
Journal:  Immunity       Date:  1997-05       Impact factor: 31.745

9.  Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains.

Authors:  T R Jones; E J Wiertz; L Sun; K N Fish; J A Nelson; H L Ploegh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

10.  Nef-induced CD4 and major histocompatibility complex class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking.

Authors:  A Mangasarian; V Piguet; J K Wang; Y L Chen; D Trono
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more
  2 in total

1.  Propanil exposure induces delayed but sustained abrogation of cell-mediated immunity through direct interference with cytotoxic T-lymphocyte effectors.

Authors:  James M Sheil; Marc A Frankenberry; Todd D Schell; Kathleen M Brundage; John B Barnett
Journal:  Environ Health Perspect       Date:  2006-07       Impact factor: 9.031

2.  EBNA2 driven enhancer switching at the CIITA-DEXI locus suppresses HLA class II gene expression during EBV infection of B-lymphocytes.

Authors:  Chenhe Su; Fang Lu; Samantha S Soldan; R Jason Lamontagne; Hsin-Yao Tang; Giorgia Napoletani; Paul J Farrell; Italo Tempera; Andrew V Kossenkov; Paul M Lieberman
Journal:  PLoS Pathog       Date:  2021-08-05       Impact factor: 7.464

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.